New Drug Development: Estimating Entry from Human Clinical Trials

Adams, Christopher; Brantner, Van V.

doi:10.2139/ssrn.428040

New Drug Development: Estimating Entry from Human Clinical Trials

FTC Bureau of Economics Working Paper No. 262

24 Pages Posted: 12 Sep 2003

See all articles by Christopher Adams

Van V. Brantner

Federal Trade Commission - Bureau of Economics

Date Written: July 7, 2003

Abstract

This paper analyses a detailed data set on drugs in human clinical trials around the world between 1989 and 2002. The data provides information on the probabilities with which drugs successfully complete the different phases of the trials and the durations of successful completions. The paper shows that success rates and durations can vary substantially across observable characteristics of the drugs, including primary indication, originating company, route of administration and chemistry. It suggests that analysis of this type of data can help us to answer questions such as: Do AIDS drugs get to market faster? Do Biotech drugs have higher probabilities of getting to market? This paper provides some general statistics for analyzing these questions.

Keywords: Pharmaceuticals, research and development, new drugs

JEL Classification: L65, O32, I10

Suggested Citation: Suggested Citation

Adams, Christopher and Brantner, Van V., New Drug Development: Estimating Entry from Human Clinical Trials (July 7, 2003). FTC Bureau of Economics Working Paper No. 262, Available at SSRN: https://ssrn.com/abstract=428040 or http://dx.doi.org/10.2139/ssrn.428040